2011 VALUE PROPOSITION

ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: ANTIBIOTIC RESISTANCE EXPERTISE AND TOOLS

APUA OBJECTIVES

- Improve institutional and governmental antimicrobial policy
- Strengthen health systems and clinical treatment capability
- Build local microbiology surveillance and diagnostics capacity
- Increase public awareness and knowledge

APUA OFFERS

- Boston-based headquarters and staff with expertise in medicine, microbiology, public health, and policy
- Affiliations with Tufts University School of Medicine and esteemed international advisory board
- Global network of local APUA chapter affiliates in 65 countries throughout Africa, Asia, South Pacific and South America
- Extensive field experience in developing countries

RESEARCH

- Ability to detect and monitor resistance emergence, spread, and evolution
- Management of large databases on antimicrobial resistance (AMR)
- Bacterial surveillance infrastructure at global and local levels
- Drug quality testing and evaluation
- Wet laboratory capacity for direct testing and analysis
- Expert advisory groups to interpret and analyze the data
- Laboratory assessments and capacity building in resource-poor countries
- Health systems research and tools to assess antibiotic supply and use
- Pharmaceutical supply and distribution
- Economics of resistance
- Coordination of large research consortia and grant programs in industrial and developing countries
- Research of bacterial spread in humans, animals, soil, and water
- Food and water safety and other bio-defense applications

EDUCATION AND ADVOCACY

- Public policy advocacy based on original research and peer-reviewed publications
- Community organization and public health education and advocacy
- Global disseminator of information via listservs, APUA blog, Web site and major media outlets
- Education material for health care providers, patients, and policy makers
- Stewardship strategies and guidelines development protocols
- Regulatory and policy advocacy and research (national and international)
- Engagement of diverse stakeholders to forge consensus on controversial policy
Full Time Staff at APUA:

**Carol Cogliani, Ed.M., M.P.H.; APUA Program Manager**
Ms. Cogliani has served as project coordinator for NIH Reservoirs of Antibiotic Resistance (ROAR) project, and a small grants program for developing countries and Pew project analyzing impact of the EU ban on antibiotics for growth promotion in agriculture. Ms. Cogliani previously worked at Harvard Medical School, Harvard School of Public Health.

**Susan Foster, Ph.D.; APUA Director of Public Policy and Education**
Dr. Foster is a specialist in pharmaceutical policy and economics with extensive experience at the WHO Essential Drugs Programme and at the World Bank’s Population, Health and Nutrition Department. Dr. Foster has extensive field experience in resource-poor countries, utilizing qualitative and quantitative research on the cost-effectiveness of health systems. Dr. Foster is a Professor of International Health at Boston University with extensive peer-reviewed publications.

**Ronald Lanoue, M.B.A.; Operations Manager of APUA**
Mr. Lanoue is responsible for financial analysis and program support to ensure the smooth operations of APUA. Mr. Lanoue has extensive experience supporting large USAID and NIH grants and has held senior administrative positions with various medical provider groups and organizations. He received his MBA from Boston University.

**Bonnie Marshall, M.T.; APUA’s Research Scientist and Editorial Consultant**
Ms. Marshall received her B.A. in Microbiology from the University of New Hampshire and a Medical Technology degree from Framingham State College. Ms. Marshall has over 25 years experience in the management and execution of bench science projects and multiple peer-reviewed journal publications concerning antimicrobial resistance surveillance.

**Dorothy Jessica Ochieng, M.Sc.; APUA Project Manager**
Ms. Ochieng is a molecular microbiologist with extensive experience in assessing ABR and AB components in African countries and in scientific database management. She coordinates projects investigating antibiotic resistance in the environment and in African countries. Ms. Ochieng has previously led collaborative Biotechnology and genomics projects.

**Aníbal Sosa, M.D.; Director of the APUA International Program**
Dr. Sosa is a microbiologist and infectious disease specialist with considerable experience managing international public health programs in developing countries. He has served as a professor of Medical Microbiology and Tropical Diseases at the University of Zulia School of Medicine and as a clinical instructor at Tufts University School of Medicine. Dr. Sosa provides technical assistance on guidelines development and laboratory strengthening programs. He was previously Director of HIV programs at a community health organization. He is the main editor of “Antimicrobial Resistance in Developing Countries”.

**Mirella Gonzalez Zulueta, M.D., PhD; Director of Translational Research**
Dr. Mirella G. Zulueta is a physician with a Ph.D. in molecular biology and biochemistry and 10+ years experience in the pharmaceutical and health care science fields. She has worked in the fields of genomics-based drug discovery and proteomics-based biomarker discovery for several biotech companies and led projects for the Ministry of Research and Innovation of Ontario, Canada. Dr. Zulueta has published over 30 peer-reviewed articles and book chapters. Dr. Zulueta’s postdoctoral training was at The Johns Hopkins University School of Medicine.

Chief Executive Officers:

**Kathleen T. Young; Executive Director of APUA**
Ms. Young has over 25 years of experience in executive administration of health care payer, provider, consumer and governmental organizations. Ms. Young is responsible for oversight of all APUA operations, programs development, and strategic initiatives and currently serves on the U.S. FDA Anti-Infective Drugs Advisory Group. Ms. Young has served as president and board member of health advocacy groups and director of strategic planning at a major international health provider organization.

**Stuart B. Levy MD; APUA Board Chairman and founder**
Dr. Levy is past president of the American Society for Microbiology and a world renowned microbiologist and physician. He discovered the mechanism for tetracycline resistance (efflux) and was among the first to document the transfer of drug resistance among animals and humans. Dr. Levy has authored over 250 scientific and medical papers as well as authoring *The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle*. He has served as advisor on health policy committees including: the NIH Fogarty Center; the U.S. Office of Technology; the EPA Subcommittees on Health and Antibiotic Resistance; and WHO Scientific Advisory Groups. Dr. Levy has also served as a consultant for the U.S. FDA, the National Institutes of Health and U.S. national security projects. He is currently a Professor of Medicine and Molecular Biology/Microbiology and the Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine, as well as a Staff Physician at the New England Medical Center.

January 25, 2011